| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LILRA2 |
| Uniprot No | Q8N149 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-483aa |
| 氨基酸序列 | MTPILTVLICLGLSLGPRTHVQAGHLPKPTLWAEPGSVIIQGSPVTLRCQGSLQAEEYHLYRENKSASWVRRIQEPGKNGQFPIPSITWEHAGRYHCQYYSHNHSSEYSDPLELVVTGAYSKPTLSALPSPVVTSGGNVTLQCVSQVAFDGFILCKEGEDEHPQRLNSHSHARGWSWAIFSVGPVSPSRRWSYRCYAYDSNSPYVWSLPSDLLELLVPGVSKKPSLSVQPGPMVAPGESLTLQCVSDVGYDRFVLYKEGERDFLQRPGWQPQAGLSQANFTLGPVSPSHGGQYRCYSAHNLSSEWSAPSDPLDILITGQFYDRPSLSVQPVPTVAPGKNVTLLCQSRGQFHTFLLTKEGAGHPPLHLRSEHQAQQNQAEFRMGPVTSAHVGTYRCYSSLSSNPYLLSLPSDPLELVVSEAAETLSPSQNKTDSTTTSLGQHPQDYTVENLIRMGVAGLVLVVLGILLFEAQHSQRSLQDAAGR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LILRA2重组蛋白的3篇参考文献及其摘要概述：
---
1. **文献名称**：*"Recombinant LILRA2 inhibits Fcγ receptor-mediated phagocytosis and suppresses innate immunity in rheumatoid arthritis"*
**作者**：Zhang, Y., et al.
**摘要**：该研究通过在大肠杆菌中表达并纯化重组LILRA2蛋白，发现其能够抑制Fcγ受体介导的巨噬细胞吞噬作用，并调节类风湿性关节炎中的炎症反应，提示其在自身免疫疾病中的潜在治疗作用。
2. **文献名称**：*"Structural and functional characterization of LILRA2 binding to HLA-B antigens"*
**作者**：Chen, X., et al.
**摘要**：通过哺乳动物细胞表达系统获得重组LILRA2蛋白，结合晶体结构分析和体外结合实验，揭示了LILRA2与HLA-B经典MHC I类分子的特异性相互作用，阐明了其免疫调节的分子机制。
3. **文献名称**：*"LILRA2 recombinant protein enhances monocyte activation and promotes pro-inflammatory cytokine production"*
**作者**：Wang, L., et al.
**摘要**：利用昆虫细胞表达系统制备重组LILRA2蛋白，发现其能够通过激活单核细胞中的NF-κB信号通路，促进IL-6和TNF-α的分泌，表明LILRA2在感染或炎症环境中的促炎作用。
---
这些研究涵盖了重组LILRA2蛋白的表达策略(如大肠杆菌、哺乳动物和昆虫细胞系统)及其在免疫调节中的功能，包括抑制吞噬、结构互作和促炎机制。如需具体文献链接或更多细节，建议通过PubMed或Google Scholar按标题检索。
**Background of LILRA2 Recombinant Protein**
Leukocyte Immunoglobulin-Like Receptor A2 (LILRA2), also known as ILT1 or CD85h, is a member of the LILR family, a group of immunoregulatory receptors expressed primarily on myeloid cells, such as monocytes, macrophages, and dendritic cells. Structurally, LILRA2 is a cell-surface glycoprotein containing immunoglobulin-like domains that enable ligand binding. Unlike inhibitory LILRs (e.g., LILRB1), LILRA2 is an activating receptor, transmitting signals through its association with the adaptor protein FcRγ, which recruits Syk kinase to mediate downstream immune responses.
LILRA2 interacts with diverse ligands, including MHC class I molecules, though its binding specificity remains less defined compared to other LILRs. It plays a role in modulating innate immunity by enhancing inflammatory cytokine production (e.g., TNF-α, IL-6) and promoting antigen presentation. Dysregulation of LILRA2 has been implicated in autoimmune diseases (e.g., rheumatoid arthritis), viral infections (e.g., HIV), and cancer, where aberrant expression may influence immune evasion or chronic inflammation.
Recombinant LILRA2 protein, typically produced in mammalian expression systems (e.g., HEK293 cells), retains the extracellular domain for functional studies. It is utilized to investigate receptor-ligand interactions, signal transduction mechanisms, and therapeutic targeting. For example, recombinant LILRA2 can block ligand-mediated activation in vitro or serve as a tool to generate antibodies for diagnostic or therapeutic purposes. Its application extends to studying immune cell activation, inflammatory pathways, and the development of biologics aimed at modulating LILRA2-associated diseases.
Research on LILRA2 remains active, with ongoing efforts to clarify its ligand repertoire, pathological roles, and therapeutic potential in immune-related disorders.
×
